Prostate-specific antigen: Current status

Ca-A Cancer Journal for Clinicians

Volumn 49, Issue 5, 1999, Pages 264-281

  Brawer, Michael K ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

CANCER DIAGNOSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0033493715     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.49.5.264     Document Type: Review

References (82)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Brawer MK, Kirby RS: Fast Facts: PSA. London, Health Press: 1998
3. Chapters, from p 389-437, ir, Oesterling JE, ed. The Urologic Clinics of North America, Vol 24. Philadelphia: WB Saunders; 1997.
4. Nixon RG, Brawer MK: Refinements in serum prostate-specific antigen testing for the diagnosis of prostate cancer in Kirby RS, O'Leary MP (eds): Recent Advances in Urology. Edinburgh, U.K., Churchill Livingstone, 1998.
5. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
6. Stamey TA, Yang N, Hay AR, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
7. Ercole CJ, Lange PH, Mathisen M, et al: Prostate specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987;138:1181-1184.
8. Ferro MA, Barnes I, Roberts JB, Smith PJ: Tumor markers in prostatic carcinoma: A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 1987;60:69-73.
9. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142:1011-1017.
10. Brawer MK, Rennels MA, Nagle RB, et al: Serum prostate specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 1989;92:760-764.
11. Irani J, Levillain P, Goujon JM, et al: Inflammation in benign prostatic hyperplasia: Correlation with prostate specific antigen value. J Urol 1997;157:1301-1303.
12. Neal DE Jr, Clejan S, Sarma D, Moon TD: Prostate specific antigen and prostatitis. I: effect of prostatitis on serum PSA in the human and non human primate. Prostate 1992;20:105-111.
13. Cooner WH, Mosley BR, Rutherford CL Jr, et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143:1146-1154.
14. Brawer MK, Lange PH: PSA in the screening, staging and follow up of early-stage prostate cancer: A review of recent developments. World J Urol 1989;7:7-11.
15. Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-75.
16. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
17. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-845.
18. Babaian RJ, Camps JL: The role of prostate specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer 1991; 68:2060-2063.
19. Bazinet M, Meshref AW, Trudel C, et al: Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994;43:44-51.
20. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
21. Cooner WH, Mosley BR, Rutherford CL Jr, et al: Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988;139:758-761.
22. Ellis WJ, Chetner MP Preston SD, Brawer MK: Diagnosis of prostatic carcinoma: The yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994;152:1520-1525.
23. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density and PSA change: Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994;74:1615-1620.
24. Rommel FM, Agusta VE, Breslin JA, et al: The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol 1994;151:88-93.
25. Moon TD, Clejan S, Neal DE Jr: Prostate-specific antigen and prostatitis. II: PSA production and release kinetics in vitro. Prostate 1992;20:113-116.
26. Mettlin C, Jones G, Averette H, al el: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers. Cancer 1993;43:42-46.
27. AUA: American Urological Association policy statement: Early detection of prostate cancer and use of transrectal ultrasound, Baltimore, 1992.
28. Brawer MK: How to use prostate specific antigen in the early detection or screening for prostatic carcinoma. CA Cancer J Clin 1995;45:148-164.
29. Williford WO, Lepor H, Dixon CM, et al: Serum PSA levels after 52 weeks of therapy with finasteride, terazosin, combination, and placebo: Results of the VA Cooperative study #359. J Urol (Suppl) Vol 155;1996;533A.
30. Carter HB, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer 1992;52:3323-3328.
31. Porter JR, Hayward R, Brawer MK: The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994; 264:151: 5:293A.
32. Porter JR, Hayward R, Brawer MK: The significance of short-term PSA change in men undergoing ultrasound guided prostate biopsy. J Urol 1994; 264:151: 5:293A.
33. Nixon RG, Wener MH, Smith KM, et al: Biological variation of prostate specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 1997;157:2183-2190.
34. Nixon RG, Wener MH, Smith KM, et al: Day to day changes in free and total PSA: Significance of biological variation. PCPD 1998;1:90-96.
35. Babaian RJ, Fritsche HA, Evans RB: Prostate specific antigen and prostate gland volume: Correlation and clinical application. J Clin Lab Anal 1990;4:135-137.
36. Benson MC, Whang IS, Olsson CA, et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-821.
37. Brawer MK, Aramburu EA, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of PSA in the diagnosis of prostatic carcinoma. J Urol 1993;150:369-373.
38. Seaman E, Whang M, Olsson CA, et al: PSA density (PSAD): Role in patient evaluation and management. Urol Clin North Am 1993;20:653-663.
39. Ohori M, Dunn JK, Scardino PT: Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995;46:666-671.
40. Lin DW, Gold MH, Ransom S, et al: Transition zone prostate specific antigen density: Lack of use in prediction of prostatic carcinoma. J Urol 1998; 160:77-82.
41. Kalish J, Cooner WH, Graham SD Jr: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994;43:601-606.
42. Maeda H, Ishitoya S, Maekawa S, et al: Prostate specific antigen density of the transition zone in the detection of prostate cancer. J Urol 1997; Vol. 2193. 158: 4:58A.
43. Maeda H, Ishitoya S, Maekawa S, et al: Prostate specific antigen density of the transition zone in the detection of prostate cancer. J Urol 1997; Vol. 2193. 158: 4:58A.
44. Zlotta AR, Djavan B, Marberger M, Schulman CC: Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction. J Urol 1997;157:1315-1321.
45. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993; 270:860-864.
46. Dalkin BL, Ahmann FR, Kopp JB: Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 1993; 150:1837-1839.
47. Etzioni R, Shen Y, Petteway JC, Brawer MK: Age-specific prostate specific antigen: A reassessment. Prostate 1996;7:70-77.
48. Aus G. (Eighth International Prostate Cancer Update). Screening for Prostate Cancer in Sweden. February 1998.
49. Borer JG, Serman J, Solomon MC, et al: Age-specific reference ranges for prostate-specific antigen and digital rectal examination may not safely eliminate further diagnostic procedures. In: Urol J, ed. 155:48A;1996:48A.
50. Stenman UH, Leinonen J, Alfthan H, et al: A complex between PSA and a 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
51. Lilja H, Christensson A, Dahlen U, et al: Prostate specific antigen in serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem 1991;37:1618-1625.
52. Christensson A, Bjork T, Nilsson O, et al: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150:100-105.
53. Luderer AA, Chen Y, Soriano TF, et al: Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 1995;46:187-194.
54. Woodrum DL, Brawer MK, Partin AW, et al: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
55. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279:1542-1547.
56. Brawer MK, Daum P, Petteway JC, Wener MH: Assay variability in serum prostate specific antigen determination. Prostate 1995;26:1-6.
57. Brawer MK, Bankson DD, Haver VM, Petteway JC: Comparison of three commercial PSA assays: Results of Restandardization of the Ciba Corning method. Prostate 1997;30:269-273.
58. Nixon RG, Meyer GE, Blase AB, et al: Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998; 160:420-425.
59. Roth HJ, Christensen-Stewart S, Brawer MK: A comparison of three free and total PSA assays. PCPD 1998;1:326-331.
60. Allard WJ, Zhou Z, Yeung KK: Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998; 44:1216-1223.
61. Brawer MK, Meyer GE, Letran JL, et al: Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-378.
62. Sokoll IJ, Bruzek DJ, Cox JL, et al: Is complexed PSA alone clinically useful? J Urol (Suppl) 1998; Vol. 159; 1998:234A.
63. Sokoll IJ, Bruzek DJ, Cox JL, et al: Is complexed PSA alone clinically useful? J Urol (Suppl) 1998; Vol. 159; 1998:234A.
64. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927-935.
65. Bostwick DG, Pacelli A, Blute M, et al: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82:2256-2261.
66. 111Indium-labeled monoclonal antibody cyt-356. J Urol 1994;152:1952-1955.
67. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
68. Haseman MK, Reed NL, Rosenthal SA: Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: Positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:703-713.
69. Kahn D, Haseman M, Libertino J, et al: Indium-111 capromab pendetide (ProstaScint) imaging of patients with rising PSA post-prostatectomy. J Urol. 1997;Vol. 157 (Suppl):204A.
70. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSM) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
71. Rochon YP, Horoszewicz JS, Boynton AL, et al: Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 1994;25:219-223.
72. Holmes EH, Greene TG, Tino WT, et al: Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate Suppl 1996;7:25-29.
73. Murphy G, Ragde H, Kenny G, et al: Comparison of prostate specific membrane antigen, and prostate-specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15:1473-1479.
74. Murphy GP, Tino WT, Holmes EH, et al: Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-271.
75. Israeli RS, Miller WH Jr, Su SL, et al: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54:6306-6310.
76. Lintula S, Stenman UH: The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 1997;157:1969-1972.
77. Israeli RS, Miller WH Jr, Su SL, et al: Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 1995;153:573-577.
78. Price DK, Woodard WL, Teigland CM: Simultaneous detection of circulating prostate-specific antigen (PSA)-expressing and prostate-specific membrane antigen (PSMA)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay. Urol Oncol 1995;1:226-233.
79. Loric S, Dumas F, Eschwege P, et al: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995;41:1698-1704.
80. Cama C, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer. II: A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-1378.
81. Sokoloff MH, Tso CL, Kaboo R, et al: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: A clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-1566.
82. Darson MF, Pacelli A, Roche P, et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997; 49:857-862.